UNSPSC 51141586: Zoniclezole

This classification denotes an anticonvulsant agent with the molecular formula C12H10ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H1C5F0K79E, chemically known as 1,2-benzisoxazole, 5-chloro-3-(1-(1h-imidazol-1-yl)ethyl)- but generally known as zoniclezole, which bears US NIH Compound Identifier 60745. European Medicines Agency schedules Zoniclezole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00186MIG.

UNSPSC 51141586 Zoniclezole, a Commodity code, shows minimal recent state and local procurement activity aligned to its nominal scope. The three recent opportunities posted under this code—Seminole County's purchase of naloxone and drug deactivation systems, Texas HHS's RFI on direct-to-manufacturer prescriptions, and MMCAP's generic multi-source pharmaceuticals RFP—involve pharmaceutical procurement but do not target zoniclezole specifically. State and local issuing bodies soliciting pharmaceutical products under this code have included county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; the code shows activity among Florida county agencies, Texas state health agencies, and Minnesota-led cooperative purchasing, though these opportunities appear to be tagged to the code without targeted demand for zoniclezole itself.

Recent pharmaceutical procurement across these jurisdictions emphasizes naloxone and opioid-response products (Seminole County), direct-to-manufacturer prescription fulfillment models (Texas HHS), and commodity-level generic drug supply through authorized wholesalers (MMCAP). Geographic spread spans Florida, Texas, and the Upper Midwest, with MMCAP's cooperative vehicle extending reach to Oregon and participating states. Seminole County issued IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline; Texas HHS issued RFI HHS0017013 on April 3, 2026, as a preliminary market-intelligence vehicle preceding formal procurement; and MMCAP, administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline for generic pharmaceuticals and OTC products. None of these opportunities document explicit demand for zoniclezole; the code's recent activity suggests either misclassification of posted opportunities or limited current market demand for the specific product at the state and local level.